Loyens & Loeff advises high-profile clients in the healthcare, life sciences and pharmaceutical sectors through a multidisciplinary team spanning regulatory, IP/IT, commercial, employment, tax, corporate and public law. Practice head Stéphanie De Smedt specialises in complex contract negotiations and data protection matters, with notable expertise in the interplay between GDPR and clinical trials regulation.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Loyens & Loeff's healthcare and life sciences practice differentiates itself by consisting of highly skilled persons who, in a fast-paced environment and critical deadlines, manage to bring the results a client expects, content- and timing-wise.’
‘Valentijn De Boe Pragmatic, business savvy, highly knowledgeable, empowers his team, values client relationship.’
‘Loyens & Loeff has a well-established healthcare platform in Northern Europe. The team is highly responsive and demonstrates strong capabilities in negotiating complex life sciences and data-related agreements.’
‘Sophisticated, efficient and a pleasure to work with.’
‘Stephanie De Smedt is sharp, commercial and provides excellent counsel.’
‘Excellent team, quality is their main obsession.’
‘Stephanie de Smedt is a talented partner with great expertise in the sector and always a practical vision on how to approach matters. It is a great pleasure working with her.’

Key clients

Galapagos
EQT Healthcare Growth Investments S.à r.l.
Pfizer Ltd
Stada Arzneimittel AG
Invacare Holdings Corporation
Benu Management

Work highlights

Advised Galapagos NV on the Belgian and Dutch tax aspects of its strategic partial demerger into two listed entities, part of a rare and complex cross-border reorganisation.

Advised EQT on its acquisition of CluePoints SA, a leading AI-driven clinical data review platform, through a competitive cross-border auction process.

Advising Pfizer on its high-stakes dispute with several EU Member States regarding payment and delivery obligations under the EU’s Covid-19 vaccine purchase agreement, including litigation before the Brussels Court and strategic advice on contractual rights across the EU.